These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 26386686)

  • 101. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
    Wyant T; Fedyk E; Abhyankar B
    J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis.
    Fratila OC; Craciun C
    J Gastrointestin Liver Dis; 2010 Jun; 19(2):147-53. PubMed ID: 20593047
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
    Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C
    J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Adalimumab in ulcerative colitis: ready for prime time.
    Danese S
    Dig Liver Dis; 2013 Jan; 45(1):8-13. PubMed ID: 22766323
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Using Vedolizumab to Treat Severe Sweet's Syndrome in a Patient With Ulcerative Colitis.
    Belvis Jiménez M; Maldonado Pérez B; Argüelles-Arias F
    J Crohns Colitis; 2018 Aug; 12(9):1134-1135. PubMed ID: 29788419
    [No Abstract]   [Full Text] [Related]  

  • 106. [Biologics treatment for ulcerative colitis].
    Nagahori M; Fujii T; Saito E; Ohtsuka K; Watanabe M
    Nihon Shokakibyo Gakkai Zasshi; 2013 Nov; 110(11):1909-15. PubMed ID: 24189818
    [No Abstract]   [Full Text] [Related]  

  • 107. A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan.
    Ikeuchi A; Kakiuchi T; Ibi A; Matsuo M
    Clin J Gastroenterol; 2021 Feb; 14(1):146-151. PubMed ID: 33040281
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.
    Chateau T; Feakins R; Marchal-Bressenot A; Magro F; Danese S; Peyrin-Biroulet L
    Am J Gastroenterol; 2020 Feb; 115(2):179-189. PubMed ID: 31809296
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East.
    Sharara AI; Al Awadhi S; Alharbi O; Al Dhahab H; Mounir M; Salese L; Singh E; Sunna N; Tarcha N; Mosli M
    Expert Rev Gastroenterol Hepatol; 2018 Sep; 12(9):883-897. PubMed ID: 30096985
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Managing Risks with Biologics.
    Click B; Regueiro M
    Curr Gastroenterol Rep; 2019 Jan; 21(2):1. PubMed ID: 30635807
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.
    de Freitas LF; Feitosa MR; Féres O; Parra RS
    Inflamm Bowel Dis; 2021 Jan; 27(2):e15-e17. PubMed ID: 33048114
    [No Abstract]   [Full Text] [Related]  

  • 112. Emerging drugs for the treatment of ulcerative colitis.
    Pastorelli L; Pizarro TT; Cominelli F; Vecchi M
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):505-21. PubMed ID: 19656075
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-α drug failure.
    Sáez-González E; Aguas M; Huguet JM; Nos P; Beltrán B
    Dig Liver Dis; 2018 Apr; 50(4):415-417. PubMed ID: 29397323
    [No Abstract]   [Full Text] [Related]  

  • 114. HIV-1 acquisition in a man with ulcerative colitis on anti-α4β7 mAb vedolizumab treatment.
    Gunst JD; Schleimann MH; Pahus MH; Østergaard L; Tolstrup M; Søgaard OS
    AIDS; 2020 Sep; 34(11):1689-1692. PubMed ID: 32769767
    [No Abstract]   [Full Text] [Related]  

  • 115. Biomarkers for colitis-associated colorectal cancer.
    Chen R; Lai LA; Brentnall TA; Pan S
    World J Gastroenterol; 2016 Sep; 22(35):7882-91. PubMed ID: 27672285
    [TBL] [Abstract][Full Text] [Related]  

  • 116. [Current and prospective biologics and small molecules in the treatment of inflammatory bowel diseases].
    Buc M
    Vnitr Lek; 2018; 64(3):280-289. PubMed ID: 29766731
    [TBL] [Abstract][Full Text] [Related]  

  • 117. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management.
    Törüner M; Akpınar H; Akyüz F; Dağlı Ü; Över Hamzaoğlu H; Tezel A; Ünsal B; Yıldırım S; Çelik AF
    Turk J Gastroenterol; 2019 Nov; 30(Suppl 4):S913-S946. PubMed ID: 32207688
    [No Abstract]   [Full Text] [Related]  

  • 118. [The management of ulcerative colitis in remission stage and the strategies for colorectal cancer surveillance in ulcerative colitis].
    Takahashi S; Kinouchi Y; Endo K; Shiga H; Shimosegawa T
    Nihon Shokakibyo Gakkai Zasshi; 2011 Dec; 108(12):1983-95. PubMed ID: 22139485
    [No Abstract]   [Full Text] [Related]  

  • 119. [Risk factors and chemoprophylaxis of ulcerative colitis-colorectal cancer].
    Pang S; Zong Y; Wu YD
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Nov; 56(11):1657-1662. PubMed ID: 36372759
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis.
    Pugliese D; Armuzzi A
    United European Gastroenterol J; 2020 Feb; 8(1):11-12. PubMed ID: 32213049
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.